Jason Weidman is a Medtronic SVP and president of its coronary and renal denervation business. [Photo courtesy of Medtronic]
As Medtronic (NYSE:MDT) continues clinical trials of its Symplicity Spyral renal denervation (RDN) system for treating hypertension, the Fridley, Minnesota-based medical device maker now hopes to win FDA approval in 2023.To better understand the technology behind what Medtronic leaders expect to become a multibillion-dollar business, Medical Design & Outsourcing spoke with Jason Weidman, Medtronic senior vice president and president of the coronary and renal denervation business, which is part of Medtronic’s cardiovascular portfolio. (We’ve edited this conversation for brevity and clarity.)
MDO: What’s the simplest way to explain renal denervation?
Weidman: The basic idea is that your kidneys are part of the body’s blood pressure control mechanis…